文献速递前列腺癌

冷冻消融后监视MRI正常者无需常规前列腺活检

Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal.
PubMed 文献 · BJU Int · 2025-05-14

该研究基于305例中危前列腺癌患者接受初次部分腺体冷冻消融后的随访数据,比较MRI可见与不可见癌症的临床显著前列腺癌检出率。结果显示MRI阳性者活检检出率43.5%,阴性者仅10.6%,且阴性者中多数为低负荷复发,可安全避免活检。

要点

  • 冷冻消融后MRI阴性者临床显著癌检出率仅10.6%,可减少活检
  • MRI阴性复发者Gleason pattern 4线性长度更短(0.6 vs 2.6 mm)
  • MRI阴性复发者更多继续主动监测(44% vs 14%,P=0.03)

核心结论

  • 冷冻消融后监视MRI阴性者可安全避免多数活检,降低费用与并发症。

研究设计与样本

  • 305例中危前列腺癌患者接受初次部分腺体冷冻消融,随访至少6个月,按协议行MRI及活检。

主要发现

  • 665次治疗后MRI中87次(13.1%)阳性、578次(86.9%)阴性。
  • 阳性MRI活检检出率43.5%,阴性MRI活检检出率10.6%。
  • 46例临床显著癌复发中28例(61%)MRI阳性、18例(39%)MRI阴性。
  • MRI可见与不可见复发的Gleason pattern 4中位线性长度分别为2.6 mm和0.6 mm(P=0.08)。
  • MRI可见与不可见复发分别有4例(14%)和8例(44%)继续主动监测(P=0.03)。

临床怎么用

  • 冷冻消融后监视MRI阴性者可减少不必要的活检,避免过度诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the clinically significant prostate cancer detection rate (csPCaDR) and pathological characteristics of magnetic resonance imaging (MRI) visible (MRIv) and MRI invisible (MRIi) cancers among men undergoing surveillance after ablative focal therapy (AFT) for intermediate-risk PCa. PATIENTS AND METHODS: A total of 305 five men enrolled in an Institutional Review Board-approved primary partial gland cryoablation (PPGCA) outcomes registry meeting the following inclusion criteria: an MRI region of interest (ROI) Prostate Imaging-Reporting and Data System 2-5 concordant with unilateral intermediate-risk disease (Gleason Grade Group [GGG] 2 or 3 disease), no gross extraprostatic extension on MRI, no GGG ≥2 contralateral to the ROI, and at least 6 months of follow-up. Protocol MRI was performed at 6, 24, 42 and 60 months. Biopsy indications evolved over time. Any Gleason pattern 4 (GP4) represented a clinically significant PCa recurrence (csPCaR). Pathological disease characteristics, csPCaDR, and salvage treatments were compared for MRIv and MRIi disease. Baseline and post-treatment characteristics were compared between MRIv and MRIi csPCaR. Ordinal and binary measures were compared with Mann-Whitney rank-sum test. Categorical testing for differences was performed with chi-square testing. RESULTS: Of 665 post-treatment MRIs, 87 (13.1%) and 578 (86.9%) were positive (+ve) and negative (-ve) for csPCaR, respectively. Biopsies were taken in 62 of the 87 +ve MRIs and 179 of the 578 -ve MRIs, with a csPCaDR of 43.5% and 10.6% for +ve and -ve MRI, respectively. Of the 46 csPCaRs, 28 (61%) and 18 (39%) were associated with +ve and -ve MRI, respectively. The median linear length of GP4 for MRIv and MRIi csPCaR was 2.6 and 0.6 mm, respectively (P = 0.08). Four (14%) and eight (44%) MRIv and MRIi csPCaRs were managed with continued active surveillance (P = 0.03). CONCLUSION: The cost and morbidity of surveillance following PPGCA can be safely reduced by avoiding biopsy in most cases with -ve MRI.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Lepor H, Persily J, Parry S, et al. Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal. BJU Int. 2025. PMID: 40365959. doi:10.1111/bju.16772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。